MariMed Inc.

MariMed Inc. is a key player in the cannabis industry, involved in the cultivation, production, and distribution of both medicinal and adult-use cannabis products across the United States and internationally. The company's diverse brand portfolio includes Nature's Heritage for cannabis genetics, flowers, and concentrates, while Kalm Fusion offers cannabis-infused chewable tablets and powdered drink mixes. Its edibles segment features natural fruit chews under the Betty's Eddies brand and a variety of baked goods like brownies and cookies from Bubby's Baked. Additionally, MariMed develops cannabidiol (CBD) formulations under the Florance brand. The company further expands its operations by licensing its proprietary brands and product formulations, and by leasing cannabis-specific facilities. MariMed Inc. was founded in 2011 and maintains its headquarters in Norwood, Massachusetts.

MariMed Inc. trades as MRMD.CN on CNQ. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $159.83M of revenue and -$14.48M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

MariMed Inc. can be compared against peers such as Cannabix Technologies Inc., The Cannabist Company Holdings Inc., C21 Investments Inc., Decibel Cannabis Company Inc., 1CM Inc., iAnthus Capital Holdings, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $39.93M, beta of 1.43, and return on equity of -27.9%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

MRMD.CN currently shows total debt of $100.09M and beta of 1.43. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.marimedinc.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.